'AutoImmunoprofiler' Builds on Success in Cancer Research to Advance Treatments for Autoimmune Diseases
UC San Francisco scientists have formed a research alliance with pharmaceutical firm Eli Lilly and Company aimed at better understanding autoimmune diseases and fostering the development of new therapies. Based on the innovative Immunoprofiler model launched at UCSF in 2017, the new initiative, called AutoImmunoprofiler, inherits the most successful aspects of its predecessor and adapts them to the study of autoimmunity. Autoimmune diseases such as lupus, inflammatory bowel disease, and typ...
Source: ucsf.edu